Provided by Tiger Trade Technology Pte. Ltd.

GRAIL, Inc.

140.12
+3.552.60%
Post-market: 139.86-0.2600-0.19%19:56 EDT
Volume:1.92M
Turnover:277.63M
Market Cap:6.26B
PE:-14.37
High:151.46
Open:138.27
Low:136.00
Close:136.57
52wk High:151.46
52wk Low:41.50
Shares:44.67M
Float Shares:40.70M
Volume Ratio:0.96
T/O Rate:4.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-9.7487
EPS(LYR):-11.1105
ROE:-16.12%
ROA:-12.03%
PB:2.46
PE(LYR):-12.61

Loading ...

Movement Alert|GRAIL, Inc. Rises 5.27% in Regular Trading, FDA Advisory Committee Unanimously Approves Galleri Safety and Supports Approval

Market Focus
·
Yesterday

Movement Alert|GRAIL, Inc. Rises 5.69% in Regular Trading, FDA Advisory Committee Votes in Favor of Galleri Multi-Cancer Detection Test

Market Focus
·
Sep 28

Grail is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Sep 28

Grail price target raised to $150 from $80 at Canaccord

TIPRANKS
·
Sep 28

U.S. Research Roundup-Chevron, Mobility Global, Tesla

Reuters
·
Sep 28

Grail Inc : Canaccord Genuity Raises Target Price to $150 from $80

THOMSON REUTERS
·
Sep 28

Canaccord Genuity Keeps Their Buy Rating on GRAIL Inc (GRAL)

TIPRANKS
·
Sep 28

Grail price target raised to $100 from $65 at Mizuho

TIPRANKS
·
Sep 25

US Research Roundup-Chevron, Exxon Mobil, GoDaddy

Reuters
·
Sep 25

Grail Shares Gain as FDA Panel Votes to Support Cancer Detection Test

Dow Jones
·
Sep 25

FDA Advisors Said it Should Approve the Grail Multicancer Blood Test. the Stock Rises Sharply.

Dow Jones
·
Sep 24

Movement Alert|GRAIL, Inc. Rises 5.97% in Regular Trading, FDA Advisory Committee Votes in Favor of Galleri Cancer Detection Test Approval

Market Focus
·
Sep 24

TD ups Grail approval probability to 95% after panel vote

TIPRANKS
·
Sep 24

PRESS Digest -Wall Street Journal - September 24

Reuters
·
Sep 24

Canaccord Genuity Remains a Buy on GRAIL Inc (GRAL)

TIPRANKS
·
Sep 24

RBC Capital Sticks to Their Hold Rating for GRAIL Inc (GRAL)

TIPRANKS
·
Sep 24

Grail's Multi-Cancer Blood Test Gets FDA Committee Vote for Premarket Approval

Dow Jones
·
Sep 24

FDA panel votes in favor of Grail’s Galleri benefits outweighing risks

TIPRANKS
·
Sep 24

US FDA Advisers Back Safety of Grail's Galleri Multi-Cancer Screening Test

THOMSON REUTERS
·
Sep 24

FDA panel says Grail’s cancer detection blood test is safe, Bloomberg says

TIPRANKS
·
Sep 24